Medical Doctor Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

Ivan Landan

Neurology Muskegon, MI Medical Doctor

NPI 1659341295 CMS profile 210148

557 Seminole Road, Muskegon, MI 49444

Open in the dashboard

General payments

$24,518

133 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, Ivan Landan of Muskegon, MI is reported in the CMS Open Payments database as having received $24,518 across 133 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $215 11
2019 General $24,303 122

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ivan Landan
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Ivan Landan were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Ivan Landan Neurology median Middle half National median
2019 $24,303 $474 $118–$2,177 $163
2020 $215 $367 $82–$2,309 $114
2021 $0 $438 $104–$2,547 $132
2022 $0 $442 $103–$2,388 $149
2023 $0 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. Genzyme Corporation $23,282 40 payments
  2. Biogen, Inc. $502 46 payments
  3. EMD Serono, Inc. $263 23 payments
  4. Acorda Therapeutics, Inc $103 5 payments
  5. Novartis Pharmaceuticals Corporation $68 2 payments
  6. Neurocrine Biosciences, Inc. $65 4 payments
  7. Kyowa Kirin, Inc. $41 2 payments
  8. Alexion Pharmaceuticals, Inc. $40 2 payments
  9. Lilly USA, LLC $30 2 payments
  10. Abbott Laboratories $28 1 payment
  11. Other $97 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $17,393 10 payments
  2. Consulting Fee $3,105 2 payments
  3. Travel and Lodging $2,054 13 payments
  4. Food and Beverage $1,960 107 payments
  5. Education $6 1 payment
Products named General payments · program years 2019–2020
  1. AUBAGIO $23,158 38 payments
  2. TYSABRI $494 44 payments
  3. TECFIDERA $352 45 payments
  4. AVONEX $292 40 payments
  5. LEMTRADA $184 2 payments
  6. Mavenclad $154 20 payments
  7. INBRIJA $103 5 payments
  8. MS DISEASE STATE $99 1 payment
  9. Luveris $96 1 payment
  10. PIPELINE-MS $85 1 payment
  11. Other $409 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

133 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record